doxazosin has been researched along with Cardiovascular Diseases in 19 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 9.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus." | 7.71 | [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. ( Hoogenberg, K; van der Tuin, J, 2002) |
| "Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin." | 6.39 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. ( Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 5.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus." | 3.71 | [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. ( Hoogenberg, K; van der Tuin, J, 2002) |
| "Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin." | 2.39 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. ( Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 16 (84.21) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 2 |
| Davis, BR | 4 |
| Pressel, SL | 1 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Hoogenberg, K | 1 |
| van der Tuin, J | 1 |
| Janssen, CA | 1 |
| Barzilay, JI | 1 |
| Bettencourt, J | 1 |
| Margolis, KL | 1 |
| Goff, DC | 1 |
| Black, H | 2 |
| Habib, G | 1 |
| Ellsworth, A | 1 |
| Force, RW | 1 |
| Wiegmann, T | 1 |
| Ciocon, JO | 1 |
| Basile, JN | 1 |
| Ebina, T | 1 |
| Arnett, DK | 2 |
| Ford, CE | 2 |
| Boerwinkle, E | 2 |
| Leiendecker-Foster, C | 2 |
| Miller, MB | 1 |
| Eckfeldt, JH | 2 |
| O'Leary, MP | 1 |
| Yusuf, S | 1 |
| Lynch, AI | 1 |
| Fulton, B | 1 |
| Wagstaff, AJ | 1 |
| Sorkin, EM | 1 |
| Lasagna, L | 1 |
| Ukhal', MI | 1 |
| Ukhal', GM | 1 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Hooper, PL | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for doxazosin and Cardiovascular Diseases
| Article | Year |
|---|---|
[Alpha blocker for protection against hypertensive target-organ damage].
Topics: Adrenergic alpha-Antagonists; Binding, Competitive; Blood Pressure; Cardiovascular Diseases; Circadi | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Dosage Forms; Doxazosin; Drug Evaluation; Heart Ve | 1995 |
5 trials available for doxazosin and Cardiovascular Diseases
11 other studies available for doxazosin and Cardiovascular Diseases
| Article | Year |
|---|---|
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabete | 2002 |
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabete | 2003 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular | 2008 |
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Diur | 2000 |
Diuretics vs. alpha blockers.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Ca | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |
Reduced heat shock proteins--a mechanism to explain higher cardiovascular events associated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Doxazosin; Heat-Shock Proteins; Humans | 2001 |
Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Doxazosin; Heat-Shock Proteins; Humans | 2001 |
Doxazosin, an inferior antihypertensive agent?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cont | 2002 |